Skip to main content

Rheumatoid Arthritis clinical trials at UCSF
5 in progress, 2 open to new patients

  • Start Time Optimization of Biologics in Polyarticular JIA

    open to eligible people ages 2–18

    STOP-JIA is a PCORI funded prospective observational study which will compare the clinical effectiveness and impact on patient reported outcomes of 3 Childhood Arthritis & Rheumatology Research Alliance (CARRA) consensus derived treatment strategies (CTPs) in new-onset polyarticular JIA (pJIA) patients to answer the critical question of when is the best time to begin biologic medications to achieve the optimal clinical and patient reported outcomes. Because the CARRA Registry will be used for data collection, all patients will be enrolled in the CARRA Registry. The standard of care treatments are chosen by the treating physician and patient/caregiver and are not randomized.

    San Francisco, California and other locations

  • Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

    open to eligible people ages 18 years and up

    The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP). The following recruitment strategies will be employed towards identifying healthy subjects with elevated anti-cyclic citrullinated peptide 3 (anti-CCP3) levels: -Pre-screening: - first degree relatives of patients with RA; - subjects at health-fairs; and - identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory arthritis in rheumatology clinics.

    San Francisco, California and other locations

  • Novel Imaging Markers for Rheumatoid Arthritis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to use magnetic resonance imaging (MRI) and high-resolution peripheral quantitative computed tomography (HR-pQCT) techniques to look at the damage and disease activity progression in the hand and wrist joints of patients with rheumatoid arthritis. The central hypothesis is that ongoing erosions and cartilage loss in rheumatoid arthritis are due to persistent inflammation, which is poorly detected by clinical examination and markers of systemic inflammation.

    San Francisco, California

  • Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

    Sorry, in progress, not accepting new patients

    The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.

    San Francisco, California and other locations

  • Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

    Sorry, in progress, not accepting new patients

    Rheumatoid arthritis patients are at increased risk of cardiovascular disease because of systemic inflammation that can persist even in patients with well-controlled joint disease. We hypothesize that adding an anti-tumor necrosis factor medication, adalimumab, to standard non-biologic therapy for rheumatoid arthritis will improve endothelial function (reduce cardiovascular risk) in these patients. The design of the trial is as follows: 18 month prospective, randomized, double-blind crossover trial comparing the addition of adalimumab to the addition of placebo. The primary endpoint is a change in endothelial cell function, as detected by brachial artery FMD, at 6 months of adalimumab treatment compared to 6 months of placebo.

    San Francisco, California